a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10581103				
	Filing Date		2006-05-31				
First Named Inventor Andre		Andre	ew Bray				
	Art Unit						
	Examiner Name						
Attorney Docket Number		er	RD-449				

			Remove			
		Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	3226010		1965-12-28	Rogers, Jr.	
2 4184591 1993-01-22 Geldma 3 4256260 1991-03-31 Fooke		Geldmacher				
		1981-03-31	Focks			
	4	4631900		1986-12-30	Mattei et al.	
			Philips, Jr.			
			Boriani et al.			
	7	5590763		1997-01-07	Focke et al.	
f you wish	to ac	dd additional U.S. Pate	nt citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581103
iling Date		2006-05-31
irst Named Inventor Andre		ew Bray
Art Unit		
xaminer Name		
Hornou Docket Number		PD 449

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	d Publication le¹ Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1											
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	pleas	se click the Add	buttor			
				FOREIG	3N PAT	TENT DOCUM	IENT	s		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			Publication Date	Name of Patentee or Applicant of cited Document			Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		T4	
	1	2004080844	wo		A1	2004-09-23	Bra	y et al.				
	2	10256370	DE		A1	2004-06-09	Foo	ske Heinz				×
	3	2614720	FR			1988-11-04	Wid	dmann Horst		NO88/086 Equivalent	02 English	×
If you wis	h to a	dd additional Foreign F	atent Do	cument	citation	information pl	lease	e click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUN	MENTS		Remove		
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country volumer publisher.								Ţ5				
	1											
If you wis	h to a	dd additional non-pater	nt literatu	re docu	ment cit	ation informat	ion p	lease click the	Add b	utton A	dd	
				EX	AMINE	R SIGNATUR	E					
Examiner	Signa	ature						Date Conside	red			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10581103
	Filing Date		2006-05-31
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Andr		ew Bray
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	RD-449

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MFEP 901.04. * Enter office that all essed the document, by the lock bits crock (WPO) Standard 513.3. ** Frequence painted consenset, the inclusion on the pase of the region of the Engeren stage of the series of the pase of the series of the pase of the series of the Engeren stage of the Series of the series of the Pase of the Series of the Engeren stage of the Series of the Series

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581103
Filing Date		2006-05-31
First Named Inventor Andre		ew Bray
Art Unit		
Examiner Name		
Attorney Docket Number		RD-449

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Charles Sherman/	Date (YYYY-MM-DD)	2007-01-02
Name/Print	Charles I Sherman	Registration Number	22998

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.